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Background: The objective of our study was to
assess hospital-to-hospital variations for the man-
agement and treatment of heart failure (HF) pa-
tients.
Methods: We performed a cross-sectional study
among randomly selected patients with ICD-10
(International Classification of Disease, 10th revi-
sion) HF hospitalised in three Swiss university
hospitals in 1999. Demographic characteristics,
risk factors, symptoms and findings at admission
and discharge medications were abstracted. The
main outcome measure was the percentage of
patients receiving appropriate management and
treatment as defined by quality of care indicators
derived from evidence-based guidelines. Quality
indicators were considered only when they could
be applied (no contra-indications).
Results: Among 1153 eligible patients with HF
the mean age (SD) was 75.3 (12.7), 54.3% were
male. Among potential candidates for specific in-
terventions, left ventricular function (LVF) was 
determined in 68.5% of patients; 53.8% received 
target dose of angiotensin converting enzyme in-
hibitors (ACEI), 86.0% any dose of angiotensin re-
ceptor blockers; 21.9% b-blockers, and 62.1% an-
ticoagulants at discharge. Compared to hospital B
(reference), the adjusted odds ratios (OR) (95%
CI) for LVF not determined were 3.82 (2.50 to
5.85) in hospital A and 3.25 (1.78 to 5.93) in hos-
pital C. The adjusted OR (95% CI) for not receiv-
ing target dose ACEI was 1.76 (0.95 to 3.26) for
hospital A and 3.20 (1.34 to 7.65) for hospital C
compared to hospital B. 
Conclusions: Apparently, important hospital-
to-hospital variations in the quality of care given
to patients with HF could have existed between
three academic medical centers.
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Heart failure (HF) is a syndrome with high
morbidity and mortality that often leads to hospi-
tal admission. Over the past ten years, the manage-
ment of HF has evolved considerably. Recent clin-
ical trials have proved that early detection and
treatment of left ventricular dysfunction (LVSD)
is particularly important [1, 2]. There is good evi-
dence that angiotensin converting enzyme in-
hibitors (ACEI) [3–6] and b-blockers improve
clinical outcome in patients with LVSD [7]. Based
on this evidence, clinical practice guidelines have
been published in the USA [8–10], in Europe [11]
and also in Switzerland [12]. However, the assess-
ment of the left ventricular function (LVF) is often
not performed and many patients do not receive
ACEI or b-blockers when appropriate. For several
years, efforts have been made to standardise the
evaluation of quality of care for HF patients [13].
In the United States, quality indicators have 
been used nationwide showing that globally 65%
of HF patients had an evaluation of their LVF and
that 69% received ACEI if they suffered from
LVSD [14]. 
For over 20 years, hospital-to-hospital varia-
tions have been observed; Wennberg et al. demon-
strated large differences in the way similar patients
were treated in different hospital settings [15–17].
Variations between hospitals were also shown 
for patients with HF, demonstrating that hospital
care is not always optimal. For example, a study 
in five US States across 69 hospitals among
Medicare beneficiaries demonstrated that the 
prescription of ACEI at discharge in patients 
with documented systolic dysfunction ranged from
54 to 94% [18]. The objective of this study was 
to assess hospital-to-hospital variations in quality






S W I S S  M E D  W K LY 2 0 0 6 ; 1 3 6 : 2 6 8 – 2 7 3  ·  w w w. s m w. c h 269
Setting and patients
A cross-sectional study included adult patients hospi-
talised for HF in three Swiss academic medical centres. All
three are urban, public, university hospitals and the main
hospital for their respective areas. Patients included in the
study were discharged from January 1 to December 31,
1999, with a principal or secondary diagnosis of HF (In-
ternational classification of diseases, 10th revision (ICD-
10) codes: I50.0, I50.1, I50.9, I11.0, I13.0 and I13.2). 
We found respectively 976 and 774 eligible patients
in two hospitals. Among those 700 patients were randomly
chosen in each hospital. In the third hospital, all 234 eli-
gible patients were included. From this total of 1634, we
excluded 134 patients transferred to another acute care fa-
cility, six patients who left the hospital against medical ad-
vice and four patients with an incoherent date of discharge.
We also excluded 306 patients for one or more of the fol-
lowing conditions: aortic stenosis (n = 111), acute myocar-
dial infarction (n = 107), chronic renal failure on dialysis
(n = 31), cor pulmonale or chronic obstructive pulmonary
disease (COPD) requiring home oxygen (n = 30), mitral
stenosis (n = 9), heart failure attributed to thyrotoxicosis
(n = 30), amyloidosis (n = 5) or thiamine deficiency (n = 1).
The final sample size was 1153.
Data 
Medical records were examined by trained abstrac-
tors in each hospital. Inter-rater reliability was assessed by
a random replicate sample of 100 charts, which were re-
abstracted [19]. The kappa values for quality of care mea-
sures were 0.91 for the determination of LVF (proportion
of positive and negative agreement 0.96 and 0.95 respec-
tively) [20] and 1.0 for anticoagulants atrial fibrillation
(proportion of positive and negative agreement 1.0 and 1.0
respectively) [20]. 
Variables, abstracted from medical records included
demographic characteristics, risk factors, and symptoms
and findings at admission. The final serum creatinine and
potassium values recorded during the hospitalisation were
also considered, as well as discharge medications and the
confirmation of AF on the admission electrocardiogram
(EKG).
Specific process quality indicators
Process quality indicators were developed from evi-
dence based guidelines in collaboration with key clini-
cians. Table 1 summarises these quality indicators (QI)
with their respective level of evidence. 
Determination of the left ventricular function (LVF) 
Determination of LVF was identified in the medical
record by the presence of the value of a previously mea-
sured ejection fraction (EF) on echocardiography, cardiac
catheterisation or radio-nuclide ventriculography. LVSD
was defined as any measured value of the EF equal to or
less than 40% documented in the chart from a previous or
current hospitalisation. If no information regarding EF
was found in the chart, the patient was classified as having
LVSD based on an existing narrative statement. 
ACEI use and dosing for systolic dysfunction
Prescription of ACEI and angiotensin receptor block-
ers (ARB) was recorded from charts. Level of target dose
ACEI used corresponded to the doses found to increase
survival in patients with LVSD in controlled clinical trials,
and was defined as: captopril 50 mg three times daily,
enalapril 10 mg twice daily, lisinopril 20 mg once daily or
ramipril 5 mg twice daily [21]. If evidence from clinical tri-
als was not available, target dose levels were based on the
manufacturer’s stated average dose, which were the follow-
ing: benazapril 20 mg once daily, fosinopril 20 mg once
daily, quinapril 10 mg twice daily, perindopril 4 mg once
daily and cilazapril 1 mg once daily [22]. This QI was de-
fined by three treatment groups among LVSD patients: 1)
patients receiving no ACEI at discharge, 2) a sub-optimal
dose of ACEI and 3) the target dose of ACEI or any dose
of ARB. We excluded patients from the analysis with any
of the following recorded contraindications to ACEI:
cough, renal insufficiency, skin rash, hyperkalaemia, angio-
oedema, neutropenia and hypotension related to ACEI use.
ß-Blockers for systolic dysfunction
To calculate the quality indicators related to b-Block-
ers prescription at discharge for patients with LVSD, pa-
tients with contraindication to b-Blockers were excluded.
These contraindications were: hypotension, asthma or








Quality Indicator Guideline Level of 
evidence ACC*
1 Identification of the underlying Patients with suspected heart failure should undergo echocardiography Class I
pathophysiology of heart failure or radionuclide ventriculography to measure the ejection fraction Level C
(if information about LVF is not available from previous tests).
2 Use and dosing of ACEI Patients with LVSD should be given trial of ACEIs unless contra- Class I
in patients with LVSD indicated. Doses of ACEIs should be titrated upward over to the doses Level A
shown to decrease mortality in large, randomised, controlled trials.
3 *Use of b-blocker in patients Patients with stable NYHA class II and III heart failure due to LVSD Class I
with LVSD should receive a b-blocker unless contraindicated. Level A
4 **Use of warfarin in patients with Heart failure patients with a history of systemic or pulmonary embolism, Class I
heart failure and atrial fibrillation recent atrial fibrillation or mobile left-ventricular thrombi should be Level A
anticoagulated to a prothrombin time ratio of 1.2–1.8 times each individual 
laboratory control time (International Normalised Ratio of 2.0–3.0).
LVF, Left Ventricular Function; ACEI, Angiotensin Converting Enzyme Inhibitor; LVSD, Left Ventricular Systolic Dysfunction; 
NYHA, New York Heart Association
*   American College of Cardiology (ACC) rating system. Class I: conditions for which there is evidence and/or general agreement that 
a given procedure/therapy is useful and effective. Class II: conditions for which there is conflicting evidence and/or a divergence of
opinion about the usefulness/efficacy of performing the procedure/therapy. Class III: conditions for which there is evidence and/or
general agreement that a procedure/therapy is not useful/effective and in some cases may be harmful. Level A: data was derived 
from multiple randomised clinical trials. Level B: data was derived from a single randomised trial or non-randomised studies. 
Level C: when consensus opinion of experts was the primary source of recommendation [10].
** Anticoagulation for atrial fibrillation not discussed in the ACC Heart Failure Guidelines but in ACC Guidelines for the management
and treatment of patients with atrial fibrillation [31].
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Anticoagulation for atrial fibrillation 
For this QI only patients with atrial fibrillation and
no known contraindication to anticoagulants were consid-
ered (recent bleeding, hepatic disease, alcoholism, coagu-
lopathy, pregnancy, gastric ulcer, recent stroke and allergy
to anticoagulants). 
Analysis
We conducted bivariate analyses first, using, when
appropriate chi-square tests, Fisher exact tests and
ANOVA methods. Then, a multivariate analysis was per-
formed to adjust for potential confounding factors using
modelling techniques [23]. Logistic regression was used to
calculate adjusted odds ratios with associated 95% confi-
dence intervals. Considering the relatively small samples
size and the large number of potential confounders, we
could not use the traditional modelling strategy defined
by Kleinbaum of looking first for an interaction term and
then by backward elimination for confounding factors
[23]. Instead, we used a priori consideration for covariate
adjustment. We included in the model any baseline param-
eter differing between hospitals to some extent and being
associated with type or severity of heart failure, irrespec-
tive of statistical significance. 
To take into account the different sampling fractions
of the three hospitals, we used the “weight statement” in
the SAS procedure “proc genmod”. None of the models
had evidence of co-linearity. For the three categories vari-
able, we used an ordinal logistic regression. The propor-
tional odds assumption was met. In sensitivity analyses, we
did two alternative analyses. We fitted a continuation odds
ratio model, and also investigated the pattern of the means
of the dependent variable across hospitals. They each
yielded qualitatively similar results, and indicated similar
trends across hospitals. All analyses were implemented
with the SAS software, version 9.1 (SAS Institute Inc.,





and findings at 
admission of patients
with heart failure 
by hospital, n = 1153.
Characteristics N (%) Hospital
or mean (SD) Hospital A Hospital B Hospital C 
N (%) N (%) N (%)
or mean (SD) or mean (SD) or mean (SD)
N = 455 N = 544 N = 154
Mean age (SD) 75.3 (12.7) 76.0 (13.3) 74.9 (12.5) 74.8 (11.8)
Sex
Male 625 (54.3) 234 (51.4) 307 (56.5) 84 (54.6)
Female 527 (45.8) 221 (48.6) 236 (43.5) 70 (45.5)
Previous history heart failure (N = 1060) 601 (56.7) 238 (54.0) 298 (64.0) 65 (42.5)
Prior myocardial infarction (N = 1129) 369 (32.7) 120 (27.2) 209 (39.1) 40 (26.1)
COPD, bronchitis, emphysema (N = 1128) 230 (20.4) 64 (14.5) 126 (23.6) 40 (26.1)
Hypertension (N = 1135) 682 (60.1) 257 (58.0) 338 (62.7) 87 (56.9)
Diabetes (N = 1137) 263 (23.1) 86 (19.6) 140 (25.8) 37 (24.0)
Current smoker (= 1105) 170 (15.4) 66 (15.1) 76 (14.5) 28 (19.6)
Symptoms and findings
PND (N = 791) 188 (23.8) 50 (11.4) 115 (57.2) 23 (15.2)
DOE (N = 1032) 790 (76.6) 292 (66.5) 396 (89.6) 102 (67.6)
Orthopnea (N = 838) 380 (45.4) 180 (41.0) 157 (63.3) 43 (28.5)
Leg oedema (N = 972) 517 (53.2) 195 (44.5) 252 (65.6) 70 (46.7)
Pulmonary rales (N = 998) 583 (58.4) 230 (52.3) 283 (69.5) 70 (46.4)
S3 gallop (N = 939) 39 (4.2) 16 (3.7) 23 (6.5) 0 (0.0)
JVD (N = 871) 280 (32.2) 110 (25.5) 126 (42.0) 44 (31.4)
Atrial fibrillation (N = 951) 261 (27.4) 75 (20.6) 148 (33.0) 38 (27.3)
COPD, Chronic Obstructive Pulmonary Disease; PND, Paroxysmal Nocturnal Dyspnoea; DOE, Dyspnoea On Exertion; 
JVD Jugular Vein Distension.
Among the 1153 cases available for analysis,
455 (39.5%) were hospitalised in hospital A, 544
(47.2%) in hospital B and 154 (13.4%) in hospital
C. The mean (SD) age of the entire sample was
75.3 (12.7), 54.3% were male, 33.7% had a previ-
ous history of myocardial infarction, 60.1% hyper-
tension, 23.1% diabetes mellitus, 20.4% COPD
and 15.4% were current smokers. 
Patient characteristics by hospitals
Table 2 illustrates the association between de-
mographic characteristics, risk factors, symptoms
and findings at admission of patients with HF by
hospital. We found significantly more patients in
hospital B either with a previous history of HF or
a prior myocardial infarction, compared to pa-
tients in hospital C. Globally, more cardiovascular
related symptoms and findings were observed in
hospital B patients. On average these patients had
seen a cardiologist more often than patients from
the other two hospitals (table 3). 
Results
S W I S S  M E D  W K LY 2 0 0 6 ; 1 3 6 : 2 6 8 – 2 7 3  ·  w w w. s m w. c h 271
Quality indicators across hospitals
The determination of LVF was assessed in
68.5% of the entire sample of HF patients. Large
variations were observed between hospitals rang-
ing from 52.1%, to 83.1%. Similar variations were
observed for the prescription of ACEI in patients
with LVSD and no contraindication to ACEI. In
hospital B, 57.9% of the patients received target
dose of ACEI or any dose of ARB, compared to
51.2% in hospital A and 39.2% in hospital C. Sim-
ilarly, we observed the following variations for pre-
scription of b-blockers at discharge in patients with
LVSD and no contraindication to b-blockers, with
respectively 43.3%, 23.2%, and 10.4% who were
prescribed b-blockers (table 4). 
Results of multivariate analyses, presented in
table 5 for the same quality indicators, show that
the risk of no LVF measured during hospitalisa-
tion was higher in hospital C (OR = 3.25, 95% 
CI: 1.78 to 5.93) and even higher in hospital A 
(OR = 3.82, 95% CI 2.50 to 5.85) compared to 
hospital B. For discharge prescription of ACEI,
the ordinal logistic regression model provided an
odds ratio (OR) of 1.76 (95% CI 0.95 to 3.26) 
for hospital A and of 3.20 (95% CI 1.34 to 7.65)
for hospital C, compared to hospital B, control-
ling age, sex, the Charlson co-morbidity index, 
history of myocardial infarction, orthopnoea,
pulmonary rales and the ejection fraction. For 
b-blockers an OR of 0.70 (95% CI 0.19 to 2.64)
for hospital C and of 3.85 (95% CI 1.50 to 9.88)





with Heart failure by
Hospital, n = 1153.
Characteristics N (%) Hospital
or mean (SD) Hospital A Hospital B Hospital C 
N (%) N (%) N (%)
or mean (SD) or mean (SD) or mean (SD)
N = 455 N = 544 N = 154
Chest X-Ray confirms heart failure (n = 738) 425 (57.6) 131 (55.0) 234 (60.0) 60 (54.6)
Mean (SD) potassium in mmol/l (n = 1099) 4.1 (0.7) 4.2 (0.5) 4.1 (0.6) 4.3 (1.1)
Mean (SD) creatinine in mmol/l (n = 1103) 114.5 (53.5) 116.4 (56.2) 112.0 (52.3) 118.3 (49.8)
Mean (SD) Minimum EF in % (n = 547) 36.5 (15.8) 39.6 (16.4) 32.8 (12.5) 39.0 (19.7)
Mean (SD) Charlson co-morbidity index  (n = 1153) 1.94 (1.43) 2.14 (1.32) 2.16 (1.42) 0.53 (0.94)
Consultation by a Cardiologist  (n = 1134) 614 (54.1) 199 (45.3) 338 (62.3) 77 (50.7)
ACEI on admission (n = 1071) 440 (41.1) 176 (41.2) 192 (39.0) 72 (47.7)
Mean (SD) length of stay (days) (n = 1153) 14.0 (15.3) 14.5 (18.3) 13.6 (12.5) 13.9 (14.1)




failure by hospital, 
n = 1153.
Indicators Total Hospital A Hospital B Hospital C
n (%) n (%) n (%) n (%)
n = 1153 n = 455 n = 544 n = 154
Quality indicators
Determination of the left ventricular function* (n = 1153) 790 (68.5) 237 (52.1) 452 (83.1) 101 (65.6)
ACEI dose in 3 categories if LVSD (n = 370)
No ACEI 52 (14.1) 17 (20.2) 24 (10.2) 11 (21.6)
Less than target dose ACEI 119 (32.2) 24 (28.6) 75 (31.9) 20 (39.2)  
Target dose ACEI or ARB 199 (53.8) 43 (51.2) 136 (57.9) 20 (39.2)    
b-blockers at discharge in patients with LVSD (n = 297) 65 (21.9) 8 (10.4) 44 (23.2) 13 (43.3) 
Anticoagulation at discharge in patients with 131 (62.1) 31 (50.8) 81 (67.5) 19 (63.3)
atrial fibrillation (n = 211)
ACEI, Angiotensin Converting Enzyme Inhibitor; LVSD, Left Ventricular Systolic Dysfunction; ARB, Angiotensin Receptor Blockers
* Out of 478 patients with LVSD (respectively 144, 275, and 59 in hospitals A, B, and C), 374 (78.2%) were identified based on value of 
an ejection fraction in the chart (respectively 132, 188, and 54 in hospitals A, B, and C), and 104 (21.8%) from a narrative statement 
in the medical chart (respectively 12, 87, and 5 in hospitals A, B, and C).
This study suggests that many patients with
HF may have received sub-standard care in the ob-
served hospitals. In addition, substantial variations
existed between these academic centres. Our find-
ings that the LVF was determined in 69%
(52–83%) of patients is similar to the results of a
study conducted in five US states among Medicare
patients hospitalised with HF in 1996 in 69 hospi-
tals [18]. In the latter study, LVF was determined
in 70% (18–97%) of patients. However, regarding
the proportion of patients receiving target dose of
ACEI, our results were better (54%) compared to
Discussion
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the US study (19%) [18]. These differences may
reflect our inclusion of patients who received ARB
in the target group, based on a recent clinical trial
showing the benefits of this type of drug in HF pa-
tients [24], while the US study did not. Our results
also are similar to those found by Krumholz and
colleagues who evaluated the care of Medicare
patients with HF in nine Connecticut hospitals.
They reported that 75% (62–92%) of the patients
had LVF documented [25]. Variations have also
been found in other studies that evaluated the
treatment and management of Medicare HF pa-
tients in the USA [26, 27]. 
Over the past few decades, differences have
been repetitively observed in the way similar 
patients are treated in one heath care setting com-
pared to another [28]. Several explanations have
been proposed for variations in medical practice.
Firstly, physicians have unique knowledge on how
to diagnose and treat illness, and that each patient
is different. Secondly, some authors argue that
variations in health care are due to differences in
available health care resources, such as hospital
beds or number of specialists. The nature and
amount of available resources could influence
physicians’ clinical decisions. A third argument is
related to practice volume [29]. Fourthly, one 
author has argued for the “enthusiasm hypothe-
sis.” This theory reflects ideas that key personali-
ties locally influence physicians in an area on 
how to treat patients [30]. Variations in health care
are associated with differences in quality of care.
One way to reduce these variations is to apply
widely distributed, evidence-based clinical guide-
lines for the management and treatment of heart
failure [8–12].
Several limitations may have biased our re-
sults. The first is specific to the Swiss health care
system. Administrative discharge data have been
monitored in Switzerland since 1998. The quality
of data is improving but is still very heterogeneous
across providers. In particular, only 234 patients
with HF were identified through ICD-10 codes 
in hospital C, which has about the same patient
volume as the two other hospitals in our study, 
corresponding to a 3 to 4-fold ratio of the number
of cases identified. A selection bias may have 
occurred because of this lower figure in the iden-
tification of HF patients in hospital C. Further-
more, in two hospitals, the entire medical chart 
was available to the abstractors, but in the third,
only the electronic discharge letter, laboratory
findings and reports from cardiology testing were
available. 
In conclusion, we found significant hospital-
to-hospital variations in the quality of care 
delivered to HF patients between three Swiss
academic medical centres for patients with HF. 
We believe that these variations are unlikely to be
fully explained by systematic errors and are there-
fore at least partially real. Our findings suggest 
that the management and treatment of HF patients
is not optimal and might be improved, according
to published evidence of effectiveness. 
Correspondence:
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Results of the multi-
variate analyses 
of quality indicators
in patients with heart
failure by hospital, 
n = 1153.
Quality indicators Hospital A Hospital B Hospital C 
n = 455 n = 544 n = 154
Adjusted OR (95% CI) Adjusted OR (95% CI) Adjusted OR  (95% CI)
LVF not determined 3.82* (2.50–5.85) 1.00 3.25* (1.78–5.93)
ACEI by dose categories if LVSD (n = 370) 1.76** (0.95–3.26) 1.00 3.20** (1.34–7.65)
– No ACEI
– Less then target dose 
ACEI
– Target dose ACEI or ARB
No b-blockers if LVSD (n = 297) 3.85*** (1.50–9.88) 1.00 0.70*** (0.19–2.64)
No anticoagulants if atrial fibrillation (n = 211) 0.87**** (0.26–2.98) 1.00 0.88**** (0.19–4.20)
LVF, Left Ventricular Function; ACEI, Angiotensin Converting Enzyme Inhibitor; LVSD, Left Ventricular Systolic Dysfunction; 
ARB, Angiotensin Receptor Blockers.
*     Controlling for age, sex, the Charlson co-morbidity index, history of hypertension, history of myocardial infarction, smoking status,
serum creatinine, orthopnoea and pulmonary rales. 
**   Results from the ordinal logistic regression (proportional odds model) summarising the effect of the three categories and 
controlling for age, sex, the Charlson co-morbidity index, history of myocardial infarction, orthopnoea, pulmonary rales and 
the ejection fraction. 
***  Controlling for age, sex, the Charlson co-morbidity index, history of myocardial infarction, orthopnoea, pulmonary rales and 
the ejection fraction. 
**** Controlling for age, sex, the Charlson co-morbidity index, history of myocardial infarction and the ejection fraction.
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